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C 
ells  translate  environmental cues into various cellular 
responses, including proliferation, differentiation, and 
death. In many cases, these responses are initiated through a 
specific interaction  between  an  extracellular ligand  and  a 
membrane-bound receptor, which then triggers a series of 
biochemical events collectively termed signal transduction. 
Much progress has been made in the identification of sec- 
ond  messengers  and  understanding  the  interactions  be- 
tween  signaling proteins.  Moreover,  correlations  between 
specific biochemical signaling events and a cellular response 
can be observed; however, demonstration of a direct cause 
and  effect  relationship  is  more  difficult  to  achieve.  Two 
observations have complicated this analysis.  First,  the bind- 
ing of a ligand to its receptor can result in several different 
responses  within  the  same  cell,  e.g.,  changes  in  growth 
characteristics,  transcription  patterns,  adhesion  properties, 
cytokine secretion profiles, et cetera. Any intracellular bio- 
chemical event induced by the ligand-receptor interaction 
might be involved in  signaling  one  of these  downstream 
responses and not the others,  a subset of responses,  or all 
of the  responses.  Second,  cells  of different  differentiative 
stages can give different responses  to  the  same ligand-re- 
ceptor interaction, e.g., proliferation in one case and apop- 
tosis in another. 
To  elucidate  the  different signaling pathways,  it is  im- 
portant to understand which biochemical changes give rise 
to particular responses. Such insights may allow the rational 
development  of new  therapeutic  agents  that  could  alter 
particular branches of these signaling pathways. For exam- 
ple, under certain circumstances, it may be advantageous to 
use pharmaceutical agents that alter the adhesion properties 
of B lymphocytes without affecting their activation, prolif- 
eration, or differentiation responses. Several recent publica- 
tions  have  described  experiments  that  define  connections 
between  signaling  components  and  specific  downstream 
cellular  responses  initiated  by engagement of the  antigen 
receptor (BCP,.) on B lymphocytes. 
B cells respond to cross-linking of their BCIks in several 
ways:  (a)  replication  and  terminal  differentiation  into 
plasma cells;  (b)  replication and differentiation to memory 
cells that then become arrested in the cell cycle; and (c) tol- 
erance to self-antigens as a result of the induction ofanergy 
and/or  cell death  (reviewed in  references  1-3).  Superim- 
posed upon these responses are other phenotypic changes, 
which may include the expression of adhesion molecules to 
alter lymphocyte homing,  the  expression of particular cy- 
tokines to help influence the overall immune response, the 
switch from expression of membrane-bound Ig to secreted 
Ig, the switching of antibody isotype to elicit different ef- 
lector functions, et cetera. 
BCR.-initiated signal transduction occurs through a mul- 
timeric  protein  complex  centered  around  membrane im- 
munoglobulin (reviewed in references 4-8).  This complex 
includes the Igo~ and Ig[3 proteins (CD79a  and b) that are 
noncovalently bound  to  the  Ix chain and are required  for 
cytoplasmic signaling.  When  the  BCR.  is  cross-linked by 
antigen or anti-Ig antibodies, one of the earliest biochemi- 
cal events  (within  seconds)  is the  activation of several ty- 
rosine kinases that interact with the BCI< complex, includ- 
ing  four  src  family members Lyn,  Fyn,  Lck,  and  Blk,  as 
well as another tyrosine kinase, Syk, which bears homology 
to  the  ZAP 70 protein  associated with  the  TCtk.  Several 
targets for these tyrosine kinases have been identified,  in- 
cluding  GTPase-activating protein  (GAP),  phosphoinosi- 
tide 3-kinase (PI3-K), the HS-1 protein, and phospholipase 
C-~/(PLC-y) (9-11). As a result ofphosphorylation, PLC-y 
becomes  activated  to  generate  diacylglycerol  (DAG)  and 
inositol trisphosphate  (InsP3).  DAG then goes on to acti- 
vate  protein  kinase  C  (PKC),  whereas  InsP3  generation 
stimulates  the  InsP3  receptor on  the  endoplasmic  reticu- 
lum,  resulting  in  the  release  of Ca  ++  from  intracellular 
stores (12,  13). 
Intracellular Ca ++ responses after BCI< engagement ap- 
pear to  have  two  components:  a  rapid,  transient  increase 
followed by a sustained oscillation of Ca  ++  concentrations 
within the cell.  The Ca ++ oscillation phase was first recog- 
nized when Ca ++ measurements were made by examining 
kinetics in individual cells (14).  When Ca ++ measurements 
are made on a population basis,  the  combination of indi- 
vidual cell oscillations tend to cancel each other out.  The 
initial transient response appears to be initiated by a release 
of Ca ++ from intracellular stores, which in turn stimulates 
the  influx  of extracellular  Ca  ++  (reviewed  in  references 
15-17).  Ca ++ concentrations from this initial  transient in- 
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tained oscillations can last for hours and are associated with 
changes in the proliferative response (18).  Using chimeric 
Ig0~ and  Ig[~ transfectants,  activation through  Igor can in- 
duce  a transient response, whereas activation through  Ig[3 
gives a sustained oscillatory response (19). 
Within  the  cytoplasm, various other signal transduction 
molecules have also been implicated in BCR signaling (re- 
viewed  in  references  4-8),  including  components  of the 
ras-raf-MAP  kinase  pathway.  Within  the  nucleus,  these 
biochemical changes result  in  altered  transcription  of im- 
portant regulatory genes, including MHC class II and cel- 
lular protooncogenes such as c-myc and c-los. The changes 
in protooncogene expression are likely to play an impor- 
tant role in regulating cellular proliferation and cell death. 
An important goal in the field is to determine how these 
biochemical changes are integrated into  particular cellular 
responses. For instance, does an increase in the concentra- 
tion of intracellular Ca  ++ induce changes in cellular prolif- 
eration or upregulation  of adhesion molecules, or is it re- 
quired  for both  downstream responses? One  approach to 
address these questions is to deplete the cells of a particular 
component that has been shown  to be altered biochemi- 
cally and then measure the cellular responses to BC1L acti- 
vation  in  these  depleted  cells.  The  prediction  is  that  if a 
component is critical for only one response, then that re- 
sponse  and  not  another  would  be  abrogated  in  depleted 
cells. 
This approach has  defined the  Lyn tyrosine kinase  as a 
critical component for cell cycle arrest mediated by BCIk 
cross-linking  in  lymphoma  cells.  Engagement  of mem- 
brane-bound Ig has been found to induce two responses in 
certain  B  cell  lymphomas:  cell  cycle  arrest  and  apoptosis 
(20-23).  If cells  were  treated  with  antisense  oligonucle- 
otides targeted to the lyn gene, however, the cell cycle ar- 
rest response was no longer observed, whereas the apopto- 
sis response was maintained (22).  Since treatment with the 
antisense  reagent  did  not  result  in  complete  depletion  of 
Lyn protein levels,  a  role  for Lyn in  apoptosis  cannot  be 
excluded.  Indeed, B  cells from lyn knockout mice may be 
resistant to anti-Ig-mediated apoptosis (Watanabe, T., per- 
sonal  communication).  Nevertheless,  these results indicate 
a critical role for Lyn in signaling cell cycle arrest, and they 
also  suggest an early bifurcation in the  signal transduction 
cascades  originating  from the  BCtL.  Other  studies  using 
antisense  oligonucleotides  indicate  that  the  Blk  kinase  is 
necessary for the apoptotic response (24). 
The paper by Takata et al.  (25)  takes a similar approach 
to investigate the role of PLC-~/2 in downstream biochem- 
ical and cellular responses. They have exploited an elegant 
system, the DT40  chicken B  cell line,  in which  the  high 
incidence  of homologous recombination after transfection 
(virtually  100%  of integrants  are targetted to  the  endoge- 
nous gene locus) greatly facilitates selection of gene knock- 
out clones (26). They show that inactivation of the PLC-~2 
gene  prevents  the  rapid  increase  in  intracellular  Ca  ++, 
InsP3  generation,  and  the  apoptotic  response  after BCR 
engagement. Not only does this indicate that PLC-~/2 is in- 
volved, but it also suggests that other PLC isoforms, which 
have been shown to be expressed in some B lymphocytes, 
are  not  able  to  substitute  for the  function  of PLC-~/2  in 
DT40 for these biochemical and cellular responses.  In contrast, 
no  differences  were  observed  in  the  protein  phosphor- 
ylation  pattern  induced  after BC1K  engagement  in  PLC- 
~/2-depleted  cells,  indicating  that  kinase  activation is  up- 
stream of PLC-~2. 
Since the inactivation of PLC-'y2 abrogates both the cal- 
cium flux and the apoptosis response,  does this mean that 
elevated intracellular free Ca ++ is required to induce apop- 
tosis? This is an important point since many signaling path- 
ways include  alteractions in intracellular  Ca  ++  concentra- 
tions  without  the  induction  of apoptosis.  An  alternative 
explanation is that the  requirement for PLC  activation in 
the apoptosis response is the activation of PKC through the 
action of DAG rather than the induction of a calcium flux. 
One experiment to test this possibility would be to activate 
the PLC-~/2-depleted cells via the BCR in the presence of 
a  calcium  ionophore  or  together  with  activation  of the 
muscarinic acetylcholine receptor (MuAR) with carbochol 
in appropriate transfectants. If the apoptotic response is re- 
stored, it could be concluded that Ca ++ elevation is neces- 
sary for apoptosis.  If apoptosis is still  not  observed,  how- 
ever,  the  result  would  suggest  that  another  downstream 
effect of PLC-~ activation is required. Indeed, the fact that 
simultaneous  activation of both  the  MuAR  and  BCR  in 
PLC-~/2-depleted  cells  is still  not  sufficient to  restore  the 
apoptosis response (25)  suggests that PLC-~2 is playing an 
additional role in signaling apoptosis aside from the genera- 
tion of DAG and InsP3. As a result of this experiment, the 
question  of  a  requirement  for  increased  Ca  ++  remains 
open. 
The Ca flux may or may not be necessary for apoptosis 
induction,  but  it is  clearly not  sufficient.  Ca ++  fluxes in- 
duced by carbochol in MuAR transfectants in the PLC-~/2 
knockout  cells  fail  to induce  apoptosis.  Thus,  some other 
effects ofmIg-initiated signal transduction are also required 
to induce apoptosis. Obviously, apoptosis is a complex re- 
sponse.  At some point,  the  signal for apoptosis must split 
into  several branches to achieve all of the downstream ef- 
fects.  The question is, where does such branching occur in 
the signaling pathways? 
Analysis of PLC-',/ function  has  also been  evaluated in 
DT40 ceils in which either the lyn and syk genes have been 
inactivated by homologous recombination (27).  In Syk-de- 
pleted cells,  mlg cross-linking is no longer able to induce 
PLC-~2  phosphorylation,  phosphoinositide  turnover,  or 
changes in intracellular Ca ++.  In contrast, in Lyn-depleted 
cells,  all  three  of these  mlg-induced  responses  are  main- 
rained, although the Ca ++ flux is somewhat delayed. Acti- 
vation of Syk is also partially reduced in Lyn-depleted cells 
(28),  suggesting that whereas Syk alone may be capable of 
inducing the Ca ++ response, Lyn may function to enhance 
the strength of the signal. 
These findings support a model for negative growth sig- 
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Figure 1.  A model for the signaling pathways responsible for the in- 
duction of cell cycle arrest and apoptosis in B lymphocytes. See text for 
details. 
naling originating from the BCR in which the branches for 
cell cycle arrest  and apoptosis bifurcate  at the  level of the 
receptor-associated  tyrosine  kinases  (Fig.  1).  The  Syk 
kinase  appears  to  activate  apoptosis  through  a  signaling 
branch  requiring  PLC-~/  and  changes  in  intracellular  free 
Ca ++  concentrations.  Apoptosis  appears  to  be  associated 
with  a  sustained  Ca ++  response  involving the  cycling of 
Ca + + in and out ofintracellular stores; a rapid, transient in- 
crease  shortly after antigen  receptor engagement  does not 
appear to be required.  However, a sustained Ca ++ response 
is probably not sufficient. It is possible that activation of the 
ras-raf-MAP kinase  pathway is  also  involved,  but  this  has 
not been tested directly. 
The Lyn tyrosine kinase appears to be responsible for the 
induction of cell cycle arrest in a signaling branch that does 
not involve PLC-3'. Two elements  downstream of Lyn in 
the  cell  cycle  arrest  pathway  are  likely  to  be  HS-1  and 
PI3-K, since they have been shown to be major phospho- 
rylation targets of activated Lyn. At this stage,  the data do 
not address the involvement of Syk in cell cycle arrest,  and 
it is possible that Syk is necessary for both responses. 
An important implication of the analysis of these signal- 
ing  pathways  relates  to  therapeutic  strategies.  There  are 
many  studies  underway  to  design  new  therapeutic  agents 
aimed at interfering with signal transduction.  This rationale 
is  based  on  the  observation  that  protooncogenes  are  fre- 
quently  found  to  be  components  of signal  transduction 
pathways,  and  that  the  genetic  alterations  associated  with 
neoplastic  transformation  generally  results  in  overexpres- 
sion  or  constitutive  activation.  However,  it  is  now  clear 
from many studies,  including  those  described  above,  that 
even malignant cancer cells can maintain growth regulatory 
pathways whose activation  can arrest  the  cell cycle or in- 
duce suicide.  Hence,  agonistic molecules  that can activate 
signaling pathways might also have therapeutic applications 
under appropriate  circumstances  (29).  In this  regard,  anti- 
bodies aimed at receptors that activate these negative growth 
pathways are being evaluated for their antitumor effects in 
experimental animals and in humans. 
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